RESUMO
BACKGROUND: Acalypha wilkesiana (AW, a popular medicinal plant has been used in traditional medicine to treat a variety of skin disorders including pityriasis versicolor and seborrheic dermatitis. As a prelude to clinical trials in humans, an experimental study was carried out to determine the spectrum of antifungal activity of 2 variants of the Acalypha wilkesiana plant. MATERIALS AND METHODS: The ethanol extract and herbal cream formulation of the dried leaves of 2 cultivars (Macrophylla & Hoffmani) of Acalypha wilkesiana were investigated for in-vitro antifungal activity by disc diffusion and micro-broth dilution techniques. Organisms tested were typed cultures of Malassezia furfur, Candida albicans and Trichophyton rubrum; and clinical strains of Microsporum canis and Epidermophyton floccosum. RESULTS: Both cultivars (Macrophylla and Hoffmanii) of the plant showed good activity against all the fungi tested except Microsporum canis (8.0±0.00; 7.00±0.00 mm). The greatest activity was observed against Trichophyton rubrum (22.0±0.00; 24.00±0.00 mm). The Minimum Inhibitory Concentration (MIC) of the crude extract ranged between 0.25 and 8 mg/ml for all organisms, while that of the herbal cream was 0.31-8mg/ml. The lowest MIC was seen with Candida albicans for both varieties of the plant. The Acalypha wilkesiana Hoffmanii demonstrated a greater activity against Candida albicans and Malassezia furufur than the A. wilkesiana Macrophylla. CONCLUSION: This study reveals Acalypha wilkesiana leaf extract has potential for development as a cream that can be used to treat superficial fungal skin infections.
RESUMO
OBJECTIVE: Increased circulating level of plasminogen activator inhibitor-1 (PAI-1) is associated with menopausal oestrogen deficiency. We therefore hypothesised that the combined oral contraceptive (COC) with spironolactone (SPL) improves insulin resistance (IR) in ovariectomised (OVX) rats by reducing circulating PAI-1. METHODS: Twelve-week-old female Wistar rats were divided into sham-operated (SHM), OVX, OVX+SPL (0.25 mg/kg), COC (1.0 µg ethinylestradiol and 5.0 µg levonorgestrel) and OVX+COC+SPL rats treated with COC and SPL daily for eight weeks. IR was assessed by homeostatic model assessment of IR (HOMA-IR). RESULTS: Data showed that OVX rats had a higher HOMA-IR value that is associated with increased visceral adiposity, triglycerides (TG), total cholesterol/high-density lipoprotein cholesterol (HDL-C), TG/HDL-C, plasma insulin, GSK-3, corticosterone and decreased 17ß-oestradiol. However, these effects were attenuated in OVX+COC, OVX+SPL and OVX+COC+SPL rats compared to OVX rats. OVX rats had lower PAI-1 than SHM rats, whereas the beneficial effect on IR and other parameters by COC or SPL was accompanied with increased PAI-1. Improvement of IR and other parameters with combined COC and SPL in OVX rats was accompanied with reduced PAI-1. CONCLUSION: Taken together, COC or SPL improves IR independent of PAI-1, whereas a combination of COC and SPL in OVX rats ameliorates IR in a PAI-1-dependent manner.